Mirvetuximab soravtansine (Elahere, AbbVie) is indicated for 'the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens'.
The dosage schedule is available in the summary of product characteristics for mirvetuximab soravtansine.
The list price of mirvetuximab soravtansine is £4,950 per 100-mg vial (excluding VAT, BNF online accessed May 2026).
The company has a commercial arrangement. This makes mirvetuximab soravtansine available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on AbbVie's webpage.